Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation

NCT04413656 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT04413656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04413656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
Lead sponsor
Shanghai Chest Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 17, 2019
Completion date
June 17, 2021
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer